Senexin C
- Product NameSenexin C
- CAS2375554-02-0
- CBNumberCB811275596
- MFC28H27N5O
- MW449.56
- MOL File2375554-02-0.mol
- MSDS FileSDS
Chemical Properties
| form | Solid |
| color | Off-white to light yellow |
Senexin C Price
| Product number | Packaging | Price | Product description | Buy |
|---|---|---|---|---|
| ChemScene CS-0376573 | 1mg | $251 | Senexin C 99.19% |
Buy |
| ChemScene CS-0376573 | 5mg | $628 | Senexin C 99.19% |
Buy |
| ChemScene CS-0376573 | 10mg | $1067 | Senexin C 99.19% |
Buy |
| ChemScene CS-0376573 | 25mg | $2232 | Senexin C 99.19% |
Buy |
| ChemScene CS-0376573 | 50mg | $3792 | Senexin C 99.19% |
Buy |
Senexin C Chemical Properties,Usage,Production
Description
Senexin C exhibits potent CDK8/19 inhibitory activity with high selectivity. Senexin C is more metabolically stable and provides a more sustained inhibition of CDK8/19-dependent cellular gene expression when compared with the prototype inhibitor Senexin B. Senexin C inhibits MV4-11 leukemia growth in a systemic in vivo model with good tolerability.Uses
Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability[1].in vivo
Senexin C (2.5 mg/kg, i.v.; 100 mg/kg, p.o.) shows good oral bioavailability[1].
Senexin C (40 mg/kg; p.o.; twice daily for 4 weeks) suppresses the systemic growth of MV4-11 AML with good tolerability[1].
Pharmacokinetic Parameters of Senexin C in eight-week-old female Balb/c mice[1].
| parameters | iv (2.5 mg/kg) | po (100 mg/kg) | ||
| plasma | tumor | plasma | tumor | |
| C0 (μg/mL) | 503 | |||
| Kel (h-1) | 0.93 | 0.06 | 0.2 | 0.1 |
| T1/2 (h) | 0.75 | 12.1 | 3.53 | 7.27 |
| Tmax (h) | 0.58 | 12 | 12 | |
| Cmax (ng/mL or ng/g) | 488 | 144 | 5728 | |
| AUC0-24 h (ng x h/ml or ng x h/g) | 331 | 6408 | 2182 | 88,600 |
| F% | 16.5% | 34.6% |
| Animal Model: | eight-week-old female Balb/c mice ( CT26 tumor mode)[1] |
| Dosage: | 2.5 mg/kg (10 mL/kg of 2.5 mg/mL Senexin C solution in 5% dextrose), 100 mg/kg (10 mL/kg of 10 mg/mL Senexin C solution in 30% propylene glycol/70% PEG-400 vehicle) |
| Administration: | 2.5 mg/kg, i.v.; 100 mg/kg, p.o. |
| Result: | Showed good oral bioavailability. |
| Animal Model: | eight-week-old female NSG mice ( AML model)[1] |
| Dosage: | 40 mg/kg |
| Administration: | p.o.; twice daily, 4 weeks |
| Result: | Suppressed the systemic growth of MV4-11 AML with good tolerability. |
IC 50
CDK8/CycC: 3.6 nM (IC50); CDK19/CycC: 2.9 nM (Kd); CDK8/CycC: 1.4 nM (Kd)References
[1] Zhang L, et al. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022; 65(4):3420-3433. DOI:10.1021/acs.jmedchem.1c01951Preparation Products And Raw materials
Senexin C Suppliers
Global(12)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 021-52996696,15000506266 15000506266 |
China | 4872 | 55 | ||
| 15317229551 | 15151849396@163.com | China | 932 | 58 | |
| 15869524721 | 3525679403@qq.com | China | 4564 | 58 | |
| 13348960310 13348960310 |
3003867561@qq.com | China | 10172 | 58 | |
| 024-88590548 18698872706 |
757984502@qq.com | China | 960 | 58 | |
| 13720134139 086-15871494362 13720134139 |
orders@jknbiochem.com | China | 7353 | 58 | |
| 021-65675885 18964387627 |
customer_service@efebio.com | China | 11963 | 58 | |
| 13053322091 13053322091 |
admin@mopaikeji.com | China | 1613 | 58 | |
| 15002134094 | marketing@targetmol.cn | China | 29874 | 58 | |
| 13370042665 18916960931 |
3623107365@qq.com | China | 17234 | 58 |
Senexin C Spectrum
2375554-02-0, Senexin CRelated Search
PROMPT×
PROMPT
The WhatsApp is temporarily not supported in mainland China
The WhatsApp is temporarily not supported in mainland China
Cancel
Determine